The Cigna Group ranked No. 14 on the Fair360 Top 50 Companies for Diversity list in 2023.
Cigna Pharmacy Management, which manages pharmacy benefits for Cigna Healthcare, is adding four new biosimilars to its formularies, supporting patient access and improving affordability.
Cigna Healthcare will prefer the following biosimilar products alongside HUMIRA on its national preferred, standard, performance, and legacy commercial formularies, effective Sept. 1, 2023:
- Cyltezo (Boehringer Ingelheim), the first FDA-approved interchangeable biosimilar to HUMIRA, a low-concentration formulation
- Adalimumab-adaz (Sandoz), high-concentration formulation, unbranded
- Hyrimoz (Sandoz), high-concentration formulation
The company will also add Hadlima (Organon), both high- and low-concentration formulations, as preferred alongside HUMIRA on its value, advantage, and total savings formularies.
“Cigna Healthcare is committed to driving greater value and lower costs where clinically appropriate for our customers and clients, and expanding access to treatment options for people that need specialty medications is core to that commitment,” said Katy Wong, Chief Pharmacy Officer, Cigna Pharmacy Management. “By placing clinically effective biosimilars on our formularies in the same position as HUMIRA, we’re ensuring that physicians and patients have choice and flexibility, as well as lower health care costs through healthy competition.”
